Laser treatment for early prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a laser treatment to destroy cancer cells in the prostate for people with early-stage prostate cancer who choose not to have surgery. It aims to target only the cancer while sparing healthy tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer was found on an MRI or PSMA PET scan and confirmed by a targeted biopsy.
- Your cancer has a Gleason score of 7 (grade group 2 or 3).
- Your PSA level is between 10 and 20 ng/mL.
- Your cancer is at clinical stage T2b (still within the prostate).
- You have decided not to have your prostate removed (radical prostatectomy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a precisely targeted laser procedure—guided by MRI images—can treat prostate cancer. It may help some men who have a certain type and location of tumor while aiming to avoid nearby sensitive structures.
This trial tests a minimally invasive prostate treatment using MRI guidance and a focal laser to destroy only the cancer spot (not the whole prostate). If you have low-to-intermediate risk, MRI-visible prostate cancer in a limited area, it may help control the cancer while potentially reducing treatment side effects.
This trial tests a gentler treatment called focal therapy that targets only the part of the prostate with cancer. It's for men whose prostate cancer has a Gleason score of 7, low PSA, and hasn't spread outside the prostate.
This trial tests a laser procedure done through the skin between the scrotum and anus, guided by MRI and ultrasound, for men with certain prostate cancer types. It aims to heat and treat prostate cancer while checking safety and outcomes over follow-up visits.
This study tests a new, less invasive treatment using targeted microwave ablation (TMA) to destroy prostate cancer tumors. It is designed for men with early-stage, low to intermediate-risk prostate cancer that hasn't spread, offering a possible alternative to surgery or radiation.
This study tests a new way to treat prostate cancer that is not visible on MRI but is detected by a special PET scan. The treatment is a focal therapy that targets only the cancer while sparing healthy tissue, and it aims to control the cancer with fewer side effects.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.